Get the Stockscreener App
0.4002
28.11%
0.0903
After Hours:
.39
-0.0102
-2.55%
Outlook Therapeutics Inc stock is traded at $0.4002, with a volume of 340.28M.
It is up +28.11% in the last 24 hours and up +25.99% over the past month.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$0.3099
Open:
$0.465
24h Volume:
340.28M
Relative Volume:
37.56
Market Cap:
$48.37M
Revenue:
$297.50K
Net Income/Loss:
$-72.19M
P/E Ratio:
-0.2337
EPS:
-1.7127
Net Cash Flow:
$-54.39M
1W Performance:
+73.82%
1M Performance:
+25.99%
6M Performance:
-76.37%
1Y Performance:
-75.19%
1-Day Range:
$0.375
$0.5069
1-Week Range:
$0.2198
$0.5069
52-Week Range:
$0.1611
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.4002 | 37.46M | 297.50K | -72.19M | -54.39M | -1.7127 |
VRTX
Vertex Pharmaceuticals Inc
|
435.95 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.12 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-25 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
OTLK stock surges over 50% pre-market, breaches key technical milestone – what’s behind this massive rally? - MSN
OTLK - Finviz
Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA - Benzinga
OTLK Stock Surges Over 50% Pre-Market, Breaches Key Technical Milestone – What’s Behind This Massive Rally? - Stocktwits
Outlook Therapeutics Wins FDA Appeal, Plans June 2026 Resubmission for ONS-5010/LYTENAVA™ (Bevacizumab) for Wet AMD Approval 1 - Minichart
Outlook Therapeutics stock surges after winning FDA appeal - Investing.com
Outlook Therapeutics (OTLK) Gains FDA Appeal Approval for Lytenava - GuruFocus
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Outlook Therapeutics says FDA finds substantial evidence of effectiveness for Lytenava in nAMD - marketscreener.com
Outlook Therapeutics wins FDA appeal, to resubmit LYTENAVA BLA in June 2026 - TradingView
[8-K] Outlook Therapeutics, Inc. Reports Material Event - Stock Titan
Outlook Therapeutics Wins Appeal Following Formal Dispute - GlobeNewswire
OTLK SEC FilingsOutlook Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Outlook Therapeutics (OTLK) seeks warrant issuances, 600M authorized shares, reverse split - Stock Titan
OTLK Technical Analysis | Trend, Signals & Chart Patterns | OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) - ChartMill
This Applied Materials analyst is no longer bullish; here are top 5 downgrades for Monday - MSN
BTIG downgrades Outlook Therapeutics (OTLK) - MSN
This Applied Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Sahm
Outlook Therapeutics Reports Second Quarter 2026 Financial Results - VisionMonday.com
OTLK Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
Outlook Therapeutics Reports Q2 2026 Financial Results, Updates on FDA Review and European Expansion of LYTENAVA (bevacizumab gamma) - Minichart
BTIG downgrades Outlook Therapeutics stock rating to neutral By Investing.com - Investing.com Australia
BTIG downgrades Outlook Therapeutics stock rating to neutral - Investing.com UK
BTIG Downgrades Outlook Therapeutics to Neutral From Buy - marketscreener.com
Outlook Therapeutics reports Q2 FY2026 net loss $4.5M, adjusted net loss $14.1M; FDA decision expected May 2026 - TradingView
Outlook Therapeutics Q2 Net Loss Narrows; Expects FDA Decision For LYTENAVA In May 2026 - RTTNews
Outlook Therapeutics (OTLK) Reports Q2 Revenue Below Expectations - GuruFocus
Outlook Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Outlook Therapeutics, Inc. 3Q 2026: Revenue $127K, EPS $(0.05) — 10-Q Summary - TradingView
OTLK: Net loss of $27.5M, negative revenue, and urgent funding needs amid ongoing U.S. regulatory delays - TradingView
Outlook Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
[10-Q] Outlook Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 - marketscreener.com
Outlook Therapeutics Q2 adjusted EPS misses analyst expectations - TradingView
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - The Manila Times
Outlook Therapeutics stock (US69012T1051): new $100 million ATM highlights financing focus - AD HOC NEWS
Outlook Therapeutics IncEnters ATM offering agreement with H.C. Wainwright for up to $100 millionSEC filing - marketscreener.com
Outlook Therapeutics Launches New $100M ATM Offering - TipRanks
Outlook Therapeutics (OTLK) registers $100M ATM offering with H.C. Wainwright - Stock Titan
Outlook Therapeuticsenters sales agreement with H.C. Wainwright to offer and sell common stock up to $100 millionSEC filing - marketscreener.com
Outlook Therapeutics (NASDAQ: OTLK) adds $100M ATM, reports $7.7M cash - Stock Titan
Outlook Therapeutics | 8-K: Current report - Moomoo
Certain Warrants of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-MAY-2026. - marketscreener.com
104,614,219 Common Stock of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-MAY-2026. - marketscreener.com
OTLK Stock Price, Quote & Chart | OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) - ChartMill
UBS Initiates Coverage of Amneal Pharmaceuticals (AMRX) With a Bullish Outlook - Yahoo Finance
Outlook Therapeutics Reports Closing of $5.0 Million Registered Direct Offering - VisionMonday.com
Outlook Therapeutics launches public offering; shares down - MSN
OTLK Price Today: Outlook Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Certain Warrants of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2026. - marketscreener.com
Certain Options of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2026. - marketscreener.com
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):